Add to ORKGOptimal treatment of heart failure is important to reduce hospitalization and mortality. In according to recommendation for treat-ment from major guideline, most patients with HF should be routinely managed with a combination of 3 types of drugs: a diuretic, an ACEI or an ARB, and a beta blocker. The value of these drugs has been established by the results of numerous large-scale clin-ical trials, and the evidence supporting a central role for their use is compelling. This review is focused on the drug treatment base
Treatment of heart failure (HF) has changed in recent years, despite the paucity of new approved dru...
Treatment of heart failure has undergone major changes in the last two decades. European and US guid...
Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to hi...
This chapter addresses the state of knowledge in the evidence-based management of heart failure (HF)...
Diagnosis and treatment for heart failure are complex task, starting from careful patients encounter...
This article provides an update on the drug treatment for heart failure (HF) mostly based on the rec...
International audienceHeart failure is the most common cardiovascular reason for hospital admission ...
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in tran...
By incremental steps over several decades of research, beta blockers have evolved ‘from bench to bed...
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in tran...
Heart failure (HF) is a major public health priority due to its epidemiological transition and the w...
The pharmacotherapy currently recommended by the American College of Cardiology and the American Hea...
Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional cardia...
After almost a decade of stagnation in clinical research for HF treatment, five large randomized tri...
Heart failure (HF) and coronary insufficiency are common amongst surgical and critical care patients...
Treatment of heart failure (HF) has changed in recent years, despite the paucity of new approved dru...
Treatment of heart failure has undergone major changes in the last two decades. European and US guid...
Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to hi...
This chapter addresses the state of knowledge in the evidence-based management of heart failure (HF)...
Diagnosis and treatment for heart failure are complex task, starting from careful patients encounter...
This article provides an update on the drug treatment for heart failure (HF) mostly based on the rec...
International audienceHeart failure is the most common cardiovascular reason for hospital admission ...
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in tran...
By incremental steps over several decades of research, beta blockers have evolved ‘from bench to bed...
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in tran...
Heart failure (HF) is a major public health priority due to its epidemiological transition and the w...
The pharmacotherapy currently recommended by the American College of Cardiology and the American Hea...
Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional cardia...
After almost a decade of stagnation in clinical research for HF treatment, five large randomized tri...
Heart failure (HF) and coronary insufficiency are common amongst surgical and critical care patients...
Treatment of heart failure (HF) has changed in recent years, despite the paucity of new approved dru...
Treatment of heart failure has undergone major changes in the last two decades. European and US guid...
Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to hi...